Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab 120 mg) / Jubbonti® (denosumab 60 mg) approved to treat cancer-related bone disease / osteoporosis across all indications of reference medicines Next milestone in Sandoz growth strategy; builds on 2025 launches of Wyost® (denosumab) / Jubbonti® (denosumab) and Tyruko® (natalizumab) in US and Afqlir® (aflibercept) in Europe Builds on established position in oncology and immunology Reinforces Sandoz commitment to helping patients access critical and potentially life-changing biologic medicines through leading global portfolio and pipeline

The release as fetched from its publisher. sandoz.com ↗